Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

204
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
204
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

226
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
226
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

331
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
331
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

180
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
180
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

208
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
208

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decoding liver injury in cystic fibrosis: How to tell drug-induced liver injury from cystic fibrosis liver disease.

World journal of gastroenterology·2026
Same author

Transcatheter Arterial Embolization for Non-Variceal Upper Gastrointestinal Bleeding: Does the Number of Prior EGDs Matter?

JGH open : an open access journal of gastroenterology and hepatology·2025
Same author

Balancing act: Tapering mycophenolate mofetil in immune checkpoint inhibitor hepatitis-strategies, outcomes, and risks.

World journal of gastrointestinal pharmacology and therapeutics·2025
Same author

Metabolic syndrome after liver transplantation: A silent threat to long-term success.

World journal of gastrointestinal pharmacology and therapeutics·2025
Same author

Endoscopic sleeve gastrectomy <i>vs</i> traditional bariatric surgery: A paradigm shift in managing metabolic dysfunction-associated steatohepatitis and cirrhosis?

World journal of gastrointestinal pharmacology and therapeutics·2025
Same author

Naltrexone-An AUDacious Approach to Treating Acute Pancreatitis in Patients with AUD.

Digestive diseases and sciences·2025

Related Experiment Video

Updated: Aug 8, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.3K

Chronic Inflammatory Demyelinating Polyneuropathy After Therapy With Infliximab Biosimilar.

Jessica Larson1, Patrick Twohig2, Kathryn Hutchins2

  • 1Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE.

ACG Case Reports Journal
|February 27, 2023
PubMed
Summary

Tumor necrosis factor-α inhibitors can rarely cause chronic inflammatory demyelinating polyneuropathy. This report details the first case of this debilitating condition following treatment with the biosimilar infliximab-dyyp (Inflectra).

Keywords:
Crohn's diseasebiosimilardemyelinationinfliximabtumor necrosis factor alpha inhibitor

More Related Videos

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

6.9K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

27.2K

Related Experiment Videos

Last Updated: Aug 8, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.3K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

6.9K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

27.2K

Area of Science:

  • Immunology
  • Neurology
  • Gastroenterology

Background:

  • Tumor necrosis factor-α (TNF-α) inhibitors are biologic therapies frequently used for inflammatory bowel disease (IBD).
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare but serious adverse effect associated with TNF-α inhibitor therapy.
  • CIDP presents as progressive muscle weakness, sensory loss, and areflexia, significantly impacting patient quality of life.

Observation:

  • This case report describes a patient who developed CIDP after receiving infliximab-dyyp (Inflectra).
  • Infliximab-dyyp is a biosimilar of infliximab, a widely used TNF-α inhibitor.
  • This represents the first documented instance of CIDP linked to this specific biosimilar agent.

Findings:

  • The development of CIDP following treatment with infliximab-dyyp (Inflectra) highlights a potential risk associated with TNF-α inhibitor biosimilars.
  • The clinical presentation and diagnostic findings were consistent with established criteria for CIDP.

Implications:

  • This case underscores the importance of vigilant monitoring for neurological adverse events in patients treated with TNF-α inhibitor biosimilars.
  • Further research may be warranted to elucidate the precise mechanisms linking TNF-α inhibition and demyelinating polyneuropathy.
  • Clinicians should consider CIDP in the differential diagnosis of new-onset neurological deficits in patients on infliximab-dyyp or similar therapies.